What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Be The Match BioTherapies, Cryoport Enter Agreement

To deliver end-to-end supply chain services to the cell and gene therapy industry

Be The Match BioTherapies and Cryoport announced a strategic partnership to deliver end-to-end supply chain services to the cell and gene therapy industry. The collaboration will support both organizations’ efforts to standardize critical elements of the cell therapy supply chain, as well as processes in apheresis and transplant center networks.
 
By pairing Cryoport’s expertise in temperature controlled logistics with Be The Match BioTherapies’ expertise in apheresis center onboarding and management, case management and logistics, clinical research, and outcomes data collection and analysis, the two organizations will offer full end-to-end supply chain and outcomes support for companies developing and delivering autologous and allogeneic cell and gene therapies. 

 
An important part of the agreement is to integrate Be The Match BioTherapies’ MatchSource® cell therapy supply chain software and Cryoport’s Cryoportal™ Logistics Management Platform. The outcome is a platform that manages more cell therapy products than any other solution in the marketplace, enabling cell and gene therapy companies to more rapidly discover, develop and deliver next-generation therapies.
 
“We are delighted to partner with Cryoport to support the growing cell and gene therapy industry,” said Chris McClain, MBA, vice president, Sales and New Business Development, Be The Match BioTherapies. “This new partnership will leverage the strengths of Cryoport and Be The Match BioTherapies to provide a unique set of standardized end-to-end workflow and logistics management services—beginning with cell harvest at apheresis centers, continuing through the supply chain, and ending with outcomes tracking—for the cell and gene therapy industry.”
 
“Be The Match BioTherapies is leading the charge to develop a more efficient and standardized cell therapy supply chain. We are pleased to join them in these industry-leading efforts and look forward to working together to support cell and gene therapy companies to more efficiently bring new medicines to patients,” said Mark Sawicki, chief commercial officer of Cryoport.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics